Insmed generated 263843000 in Q4 2025 revenue, led by 144600000 from BRINSUPRI and 119200000 from ARIKAYCE. Operating expenses increased significantly, resulting in a net loss of 328485000 for the quarter.

Insmed achieved strong third-quarter financial results with 52% total revenue growth year-over-year, driven by ARIKAYCE expansion and the U.S. launch of BRINSUPRI. The company raised full-year guidance and reported continued clinical and regulatory progress across its pipeline.

Insmed delivered $107.4 million in revenue for Q2 2025, reflecting 19% year-over-year growth, with ARIKAYCE sales increasing across all regions. However, the company posted a net loss of $321.7 million due to rising R&D and SG&A expenses.

Insmed delivered strong revenue growth for ARIKAYCE in Q1 2025 across all regions, while advancing key clinical programs and preparing for the potential launch of brensocatib later in the year.

Insmed reported total revenue of $104.4 million for Q4 2024, reflecting a 24.8% year-over-year increase. Net loss for the quarter was $235.5 million, widening from $186.1 million in Q4 2023. The company also reported an increase in operating expenses, primarily due to increased R&D and SG&A costs. Insmed ended the year with approximately $1.4 billion in cash, cash equivalents, and marketable securities.

Insmed reported Q3 2024 financial results, with total revenue reaching $93.4 million, an 18% increase year-over-year. The company is on track to file an NDA for brensocatib in Q4 2024 and anticipates a potential U.S. launch in mid-2025. Insmed ended the quarter with approximately $1.5 billion in cash, cash equivalents, and marketable securities.

Insmed reported a 17% increase in total revenue to $90.3 million for Q2 2024, driven by ARIKAYCE sales growth. The company is preparing for the potential launch of brensocatib in bronchiectasis and continues to advance its pipeline programs.

Insmed reported first-quarter 2024 financial results, highlighting a 16% increase in total revenue to $75.5 million compared to Q1 2023. The company is progressing with its ARIKAYCE commercialization and advancing its brensocatib and TPIP clinical programs.

Insmed reported Q4 2023 total revenue of $83.7 million, a 41% increase compared to Q4 2022. The company's net loss for the quarter was $186.1 million, or $1.28 per share. Insmed ended the year with $780.4 million in cash, cash equivalents, and marketable securities.

Insmed reported a total revenue of $79.1 million for Q3 2023, a 17% increase compared to Q3 2022. The growth was primarily driven by ARIKAYCE sales in the U.S. and Japan. The company is progressing its pipeline, including brensocatib and TPIP.

Insmed reported Q2 2023 financial results, highlighted by total revenue of $77.2 million, an 18% increase compared to Q2 2022. The growth was primarily driven by ARIKAYCE sales, which reached their highest level since launch. The company raised its full-year 2023 revenue guidance for ARIKAYCE to $295 million to $305 million. Insmed reported a net loss of $244.8 million, or $1.78 per share.

Insmed Incorporated reported financial results for the first quarter ended March 31, 2023. Total revenue was $65.2 million, a 23% increase year-over-year. The company had a net loss of $159.8 million, or $1.17 per share.

Insmed reported a strong finish to 2022 with significant commercial and clinical execution. Screening is complete in adult patients in the Phase 3 ASPEN study of brensocatib in bronchiectasis, with topline results expected in the second quarter of 2024. ARIKAYCE global revenue grew 30% in 2022 compared to 2021.

Insmed reported a 45% year-over-year increase in ARIKAYCE revenue for Q3 2022, reaching $67.7 million. The company is progressing with clinical trials and secured financing to support its four pillars. Insmed reported a net loss of $131.1 million, or $1.09 per share.

Insmed reported a strong second quarter in 2022, with ARIKAYCE revenue growing 44% year-over-year. The company's clinical programs are progressing as expected, and they are reiterating their guidance of at least 30% revenue growth in 2022 and cash runway into 2024.

Insmed reported a 32% year-over-year growth in ARIKAYCE revenue for Q1 2022, reaching $53.1 million in total revenue. The company is progressing with seven clinical trials and anticipates its cash on hand will support its ongoing business into 2024.

Insmed reported Q4 2021 total revenue of $56.1 million, compared to $41.4 million for Q4 2020. The company's cash position is expected to support ongoing programs into 2024.

Insmed reported a revenue of $46.8 million for the third quarter of 2021, compared to $43.6 million for the third quarter of 2020. The company's GAAP net loss was $112.7 million, or $0.96 per share, compared to a GAAP net loss of $63.7 million, or $0.63 per share, for the third quarter of 2020. The company had cash and cash equivalents of $846.6 million as of September 30, 2021.

Insmed reported total revenue of $45.4 million for the second quarter of 2021, compared to $42.5 million for the second quarter of 2020. The company's GAAP net loss was $117.3 million, or $1.07 per share, compared to a GAAP net loss of $61.9 million, or $0.64 per share, for the second quarter of 2020. ARIKAYCE was launched in Japan in July 2021.

Insmed reported a strong start to 2021, securing approval of ARIKAYCE in Japan, demonstrating steady ARIKAYCE performance in the U.S., and advancing its European launch. The company continues to enroll patients in clinical trials and is working to advance TPIP to Phase 2 clinical development.

Insmed's total revenue for the fourth quarter ended December 31, 2020 was $41.4 million, compared to total revenue of $45.7 million for the fourth quarter of 2019. The company reported a GAAP net loss of $102.2 million, or $1.00 per share, compared to a GAAP net loss of $53.0 million, or $0.59 per share, for the fourth quarter of 2019. As of December 31, 2020, Insmed had cash and cash equivalents of $532.8 million.

Insmed reported a productive third quarter with significant progress across its programs. ARIKAYCE performance was maintained in the U.S., marketing authorization was granted in the European Union, and an sNDA was approved by the U.S. FDA. Plans to initiate a global Phase 3 study of brensocatib in NCFBE and a Phase 1 study of TPIP were also advanced.

Insmed reported strong sequential growth in ARIKAYCE U.S. sales and continued to advance brensocatib, which received Breakthrough Therapy Designation from the FDA. The company also received a positive CHMP opinion for ARIKAYCE in the European Union.

Insmed reported their Q1 2020 financial results, highlighting their support for the NTM lung disease community and uninterrupted supply of ARIKAYCE amidst the COVID-19 pandemic. They had cash and cash equivalents of $428.9 million as of March 31, 2020, and total operating expenses for the first quarter of 2020 were $88.8 million.

Insmed reported a transformative year in 2019, marked by the first full year of the ARIKAYCE U.S. launch and advancements in the global infrastructure. The company also announced positive top-line Phase 2 data for INS1007 in non-cystic fibrosis bronchiectasis.